Stryker Corporation reported its full year (FY) 2025 financial results, highlighting a 15.7% increase in MedSurg and Neurotechnology net sales. The growth was driven primarily by higher unit shipments across all MedSurg and Neurotechnology businesses, with acquisitions and divestitures contributing 4.7% to net sales growth during the period. Sales pricing contributed an additional 0.7% to the increase. Operating income as a percentage of net sales in the MedSurg and Neurotechnology segment rose to 29.9% in FY 2025, up from 29.6% in the previous year. The Orthopaedics segment also saw an increase in operating income as a percentage of net sales, reaching 29.8% in FY 2025. Key factors influencing these results included higher sales volumes and improved sales pricing, partially offset by increased manufacturing and supply chain costs. Stryker Corporation continued to prioritize its long-term capital allocation strategy, with a focus on acquisitions, dividends, and share repurchases. The company’s innovative product and service offerings in MedSurg, Neurotechnology, and Orthopaedics contributed to its impact on more than 150 million patients annually.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stryker Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000310764-26-000010), on February 11, 2026, and is solely responsible for the information contained therein.